Skip to content

Plus Therapeutics rallies on Orphan Drug tag for glioblastoma treatment

September 1, 2020

Nano cap Plus Therapeutics (NASDAQ:PSTV) jumps 24% premarket on robust volume in reaction to U.S. Orphan Drug status for lead drug Rhenium NanoLiposomes (RNL) for the treatment of recurrent glioblastoma, an aggressive type of cancer of the brain or spinal cord.

RNL, designed to deliver a very high dose of radiation (up to 25x more than external beam radiation therapy) directly into the brain tumor, is currently being tested in a Phase 1 dose-finding study called ReSPECT.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: